Atlas Trials

Phase II Clinical Trial of Recombinant COVID-19 Variant Vaccine (Sf9 Cell)

Clinical trial NCT05770180 · COMPLETED

Trial details

NCT number
NCT05770180
Sponsor
WestVac Biopharma Co., Ltd.
Status
COMPLETED
Phase
Phase 2
Study type
INTERVENTIONAL
COVID-19
Start date
2023-03-30
Primary completion
2023-07-30
Enrollment
450

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.